No Data
No Data
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics Reaffirms Treatment Supply After Hurricane Helene
Heron Therapeutics: CINVANTI, in Combination With Other Antiemetic Agents, Is Indicated in Adults for Prevention of Nausea and Vomiting Associated With Cancer Chemotherapy >HRTX
Heron Therapeutics: Marion Facility Is Believed to Supply Up to 60% of the IV Fluid Market in U.S. >HRTX
Heron Therapeutics: Potential Disruption in Supply of Intravenously Administered Fluids Is Result of Temporary Closure of Suppliers' Manufacturing Site in Marion, N.C., Impacted by Hurricane Helene >HRTX
Express News | Heron Therapeutics Reaffirms Availability and Ample Supply of Cinvanti®, Sustol®, and Aponvie® as Alternatives During the Potential Shortage of Intravenous Fluids
No Data
No Data